Chester County News and Community Website
CHESTERBROOK, PA — Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, announced a poster …
Read More
DEVON, PA — Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, has reported financial results for the first quarter …
Read More
As seasons change, there’s often a great deal of shuffling and movement, including common allergy triggers like trees, pollen, mold spores, dust and dander along with pesky sinus pressure. Combined …
Read More
Nasal congestion, due to colds or seasonal allergies, affects almost everyone at some point. This year, with both seasonal allergies and COVID-19 running rampant, it may be especially difficult to …
Read More
MALVERN, PA — Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy …
Read More
You may have heard the story about how penicillin was discovered by accident: A Scottish researcher studying the influenza virus came back from vacation to find mold on a culture …
Read More
The sudden onset of stroke symptoms can happen to anyone at any time, making education about the signs and symptoms of a “brain attack” the first line of defense to …
Read More DEVON, PA — Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, announced the Company has received guidance from the …
Read More
WASHINGTON, D.C. — The U.S. Food and Drug Administration approved Farxiga (dapagliflozin) oral tablets to reduce the risk of kidney function decline, kidney failure, cardiovascular death and hospitalization for heart …
Read More
WASHINGTON, D.C. — The U.S. Food and Drug Administration has granted accelerated approval to Jemperli (dostarlimab) for treating patients with recurrent or advanced endometrial cancer that has progressed on or …
Read More